3. Cohen BM, Baldessarini RJ, Pope HG Jr, et al. Neuroleptic malignant syndrome. N Engl J Med1985; 313:1293. Letter.
4.
4. Adityanjee et al. /Int J Geriatr Psychiatry1992; 7:834–846.
5.
5. Junaid O, Biswas A, Jones RG. Neuroleptic malignant syndrome. Int J Geriatr Psychiatry1992; 8:524–531.
6.
6. Guze BH, Baxter LR Jr.Neuroleptic malignant syndrome. N Engl J Med1985; 313:163–166.
7.
7. Pope HG Jr, Keck PE Jr, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry1986; 143:1227–1233.
8.
8. Shalev A, Munitz H.The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand1986; 73:337–347.
9.
9. Gelenberg AJ, Bellinghausen B, Wojick JD, et al. A prospective survey of neuroleptic malignant syndrome in a short-term psychiatric hospital. Am J Psychiatry1988; 145:517–518.
10.
10. Keck PE Jr, Pope HG Jr, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome: a prospective study. Am J Psychiatry1987; 144:1344–1346.
12. Coons DJ, Hillman FJ, Marshall RW. Treatment of neuroleptic malignant syndrome with dantrolene sodium: a case report. Am J Psychiatry1982; 139:944–945.
13.
13. Goekoop JG, Carbaat PA. Treatment of neuroleptic malignant syndrome with dantrolene. Lancet1982; 2:49–50. Letter.
15. Blue MG, Schneider SM, Noro S, et al. Successful treatment of neuroleptic malignant syndrome with sodium nitroprusside. Ann Intern Med1986; 104:56–57.
16.
16. Lazarus A.Treatment of neuroleptic malignant syndrome with electroconvulsive therapy. J Nerv Ment Dis1986; 174:47–49.
17.
17. Hughes JR. ECT during and after the neuroleptic malignant syndrome: a case report. J Clin Psychiatry1986; 47:42–43.
18.
18. Rosebush PI, Stewart T, Mazurek MF. The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care?Br J Psychiatry1991; 159:709–712.